 HONOLULU--BUSINESS WIRE--The Sonic Fund II, L.P. Sonic, which beneficially owns approximately 6.8 of the outstanding common stock of Adverum Biotechnologies, Inc. NASDAQ: ADVM the Company or Adverum, today commented on the Companys April 28 announcement of a Suspected Unexpected Serious Adverse Reaction SUSAR of hypotony in its INFINITY clinical trial evaluating ADVM-022 gene therapy for the treatment of diabetic macular edema DME: This unfortunate announcement is a stark i 